Translational Development Acquisition Corp. Ordinary Shares Total Liabilities
Translational Development Acquisition Corp. Ordinary Shares total liabilities. Based on the latest financial reports, Translational Development Acquisition Corp. Ordinary Shares (TDAC) has total liabilities worth $7.79 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Translational Development Acquisition Co current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
Total liabilities of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025. This chart illustrates how Translational Development Acquisition Corp. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data.
Translational Development Acquisition Corp. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Translational Development Acquisition Corp. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OP Bancorp
NASDAQ:OPBK
|
USA | $2.42 Billion |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
Korea | ₩101.65 Billion |
|
Jiangxi Changyun Co Ltd
SHG:600561
|
China | CN¥3.20 Billion |
|
Xsolla SPAC 1 Class A Ordinary Shares
NASDAQ:XSLL
|
USA | $405.10K |
|
Alta Equipment Group Inc
NYSE:ALTG
|
USA | $1.36 Billion |
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
USA | $10.09 Million |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
Germany | €20.17 Billion |
|
Coca Cola HBC AG
LSE:CCH
|
UK | GBX10.78 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Translational Development Acquisition Corp. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Translational Development Acquisition Co total assets.
Liquidity & Leverage Metrics
Translational Development Acquisition Corp. Ordinary Shares Total Liabilities Ratios Explained
Translational Development Acquisition Corp. Ordinary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Translational Development Acquisition Corp. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
The table below shows the annual total liabilities of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.58 Million | +5.34% |
| 2024-12-31 | $6.25 Million | +1125.83% |
| 2023-12-31 | $509.68K | +10.96% |
| 2022-12-31 | $459.34K | -- |
About Translational Development Acquisition Corp. Ordinary Shares
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.